{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:36Z","timestamp":1791924756095,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ctrv.2025.103011","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T22:27:46Z","timestamp":1754778466000},"page":"103011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Immune checkpoint inhibitor-related neurotoxicity: Incidence and management. A systematic review and meta-analysis"],"prefix":"10.1016","volume":"140","author":[{"given":"Dorte Lisbet","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten Bogh","family":"Juhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna Markovna","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Haagen","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Denise","family":"Santomasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.103011_b0005","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2025.103011_b0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/clinpract13010003","article-title":"The role of immune checkpoint inhibitors in cancer therapy","volume":"13","author":"Basudan","year":"2022","journal-title":"Clin Pract"},{"key":"10.1016\/j.ctrv.2025.103011_b0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10555-025-10260-8","article-title":"Lessons learned from a decade of immune checkpoint inhibition: the good, the bad, and the ugly","volume":"44","author":"Adashek","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2025.103011_b0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103011_b0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006500","article-title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review","volume":"11","author":"Barron","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103011_b0030","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103011_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103011_b0040","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ctrv.2025.103011_b0045","doi-asserted-by":"crossref","unstructured":"Bruna J, Argyriou AA, Anastopoulou GG, Alemany M, Nadal E, Kalofonou F, et al. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. J Peripher Nerv Syst. 2020;25:171-7. DOI: 10.1111\/jns.12371.","DOI":"10.1111\/jns.12371"},{"key":"10.1016\/j.ctrv.2025.103011_b0050","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1111\/ene.15942","article-title":"Predictors for the development of neurological immune-related adverse events of immune checkpoint inhibitors and impact on mortality","volume":"30","author":"Yan","year":"2023","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ctrv.2025.103011_b0055","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2217\/imt-2023-0273","article-title":"Patterns of neurological adverse events among a retrospective cohort of patients receiving immune checkpoint inhibitors","volume":"16","author":"Hunting","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctrv.2025.103011_b0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103011_b0065","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.103011_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2020.102029","article-title":"Neuropeptide Y is involved in the regulation of quiescence of hematopoietic stem cells","volume":"80","author":"Ulum","year":"2020","journal-title":"Neuropeptides"},{"key":"10.1016\/j.ctrv.2025.103011_b0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami","year":"2021","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2025.103011_b0080","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ctrv.2025.103011_b0085","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s10637-022-01232-8","article-title":"The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis","volume":"40","author":"Meng","year":"2022","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2025.103011_b0090","unstructured":"Higgins JPT TJ, Chandler J, Cumpston M, Li T. Page MJ, Welch VA. Cochrane Handbook for systematic reviews of interventions, version 6.3.: Cochrane; 2022."},{"key":"10.1016\/j.ctrv.2025.103011_b0095","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2025.103011_b0100","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1002\/hsr2.178","article-title":"Arcsine-based transformations for meta-analysis of proportions: pros, cons, and alternatives","volume":"3","author":"Lin","year":"2020","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.ctrv.2025.103011_b0105","unstructured":"National Institutes of Health Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0: U.S. Department of Health and Human Services; 2017."},{"key":"10.1016\/j.ctrv.2025.103011_b0110","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103011_b0115","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103011_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","article-title":"Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese adverse Drug Event Report database","volume":"145","author":"Sato","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2025.103011_b0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12885-020-07741-0","article-title":"Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.103011_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ctrv.2025.103011_b0135","first-page":"A384","article-title":"Incidence and risk factors for stroke associated with immune checkpoint inhibitor therapy in cancer patients using real-world clinical data","volume":"8","author":"Jain","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103011_b0140","first-page":"779","article-title":"Cancer-associated stroke: Pathophysiology, detection and management (Review)","volume":"54","author":"Dardiotis","year":"2019","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2025.103011_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103011_b0150","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1474-4422(23)00335-6","article-title":"Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study","volume":"22","author":"Fonseca","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ctrv.2025.103011_b0155","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad169","article-title":"Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity","volume":"5","author":"Farina","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.ctrv.2025.103011_b0160","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1474-4422(23)00413-1","article-title":"Immune-checkpoint inhibitors and neurological adverse events","volume":"22","author":"Tummala","year":"2023","journal-title":"Lancet Neurol"},{"issue":"suppl","key":"10.1016\/j.ctrv.2025.103011_b0165","first-page":"1","article-title":"Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study","volume":"23","author":"Yang","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ctrv.2025.103011_b0170","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1136\/annrheumdis-2020-217018","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO\u2019s adverse drug reactions database","volume":"81","author":"Nguyen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ctrv.2025.103011_b0175","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.ctrv.2025.103011_b0180","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2025.103011_b0185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103011_b0190","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103011_b0195","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103011_b0200","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, et al. National Comprehensive Cancer Network, Philadelphia, PA: Management of immunotherapy-related toxicities, version 1.2025. 2025."},{"key":"10.1016\/j.ctrv.2025.103011_b0205","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.22.01602","article-title":"Neurological manifestations as a harbinger of myocarditis in patients treated with immune checkpoint inhibitors","volume":"41","author":"Rossi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103011_b0210","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.103011_b0215","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ctrv.2025.103011_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.662856","article-title":"Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and meta-analysis of comparative evidence","volume":"12","author":"Ipe","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.ctrv.2025.103011_b0225","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103011_b0230","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/17474086.2016.1122515","article-title":"ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies","volume":"9","author":"Tersteeg","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.ctrv.2025.103011_b0235","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cjco.2020.11.004","article-title":"Plasma exchange for immune checkpoint inhibitor-induced myocarditis","volume":"3","author":"Yogasundaram","year":"2021","journal-title":"CJC Open"},{"key":"10.1016\/j.ctrv.2025.103011_b0240","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltac012","article-title":"Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?","volume":"2","author":"Katsumoto","year":"2022","journal-title":"Immunother Adv"},{"key":"10.1016\/j.ctrv.2025.103011_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114028","article-title":"Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"203","author":"Ruf","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103011_b0250","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2025.103011_b0255","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103011_b0260","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barre syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ctrv.2025.103011_b0265","doi-asserted-by":"crossref","unstructured":"Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2014;2014:CD002063. DOI: 10.1002\/14651858.CD002063.pub6.","DOI":"10.1002\/14651858.CD002063.pub6"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T16:52:30Z","timestamp":1762015950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":53,"alternative-id":["S0305737225001331"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103011","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-related neurotoxicity: Incidence and management. A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103011"}}